NIBS Evidence-Based Toolkit

ℹ️

About This Clinical Decision Support Tool

Evidence compiled from recent meta-analyses, systematic reviews, and RCTs. Each modality is assessed independently per disorder — effect sizes and evidence levels reflect single-modality outcomes using Oxford CEBM grading (A–D). Response rates reflect active vs. sham-controlled trials.

📊 Per-modality effect sizes 🎓 Oxford CEBM A–D grading 🏥 FDA/Regulatory status ⚡ Protocol parameters 🚫 Contraindications 📚 Key references

Disorders

Modalities

FDA-Cleared Uses

—

Level A Modality-Uses

2025

Last Updated

Oxford CEBM Evidence Levels

Level A – Consistent meta-analyses / multiple high-quality RCTs

Level B – Single RCT or inconsistent meta-analyses

Level C – Observational / small pilot RCTs

Level D – Expert opinion / case series / emerging

🔍

Category:

Modality:

Min Evidence:

FDA Approved:

⚠️ Clinical Disclaimer This tool is intended for qualified healthcare professionals only. All effect sizes reflect single-modality outcomes from published meta-analytic data. Information is for educational and clinical decision-support purposes and does not replace individual clinical judgment, patient assessment, or institutional protocols. FDA approval status reflects US regulatory data as of November 2025.